GreenLight Biosciences Holdings

NasdaqGM:GRNA Stock Report

Market Cap: US$45.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

GreenLight Biosciences Holdings Past Earnings Performance

Past criteria checks 0/6

GreenLight Biosciences Holdings's earnings have been declining at an average annual rate of -41.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been growing at an average rate of 577.3% per year.

Key information

-41.67%

Earnings growth rate

93.21%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate577.34%
Return on equity-717.16%
Net Margin-1,521.00%
Last Earnings Update31 Mar 2023

Recent past performance updates

Recent updates

Seeking Alpha Oct 12

GreenLight Biosciences cutting 25% of staff as part of realignment

GreenLight Biosciences (NASDAQ:GRNA)is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus on proof of concept of its technology platform with its COVID vaccine and advancing ITS shingles program in collaboration with THE Serum Institute of India. Regarding plant health, GreenLight (GRNA) will continue to advance fungicides and insecticides in its pipeline.
Seeking Alpha Aug 12

GreenLight Biosciences launches $109M in financing

GreenLight Biosciences (NASDAQ:GRNA) announced a private placement of ~$109M; financing includes participation from new and existing institutional investors. The company has agreed to sell ~27.8M shares to a select group of institutional and accredited investors at $3.92/share. The company plans to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and equivalents, is expected to be sufficient to fund operations through the 1H23. Shares trading 2.8% higher premarket.
Seeking Alpha Aug 01

GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine

GreenLight Biosciences (NASDAQ:GRNA) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine. After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months. The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product. (GRNA) is up 3.6%.
Seeking Alpha Apr 05

GreenLight Biosciences: Synthesizing Cell-Free RNA

GreenLight Biosciences makes affordable and accessible RNA products for human health and agriculture. The company’s cell-free RNA manufacturing platform allows for cost-effective and scalable production of RNA. The company became a publicly listed and Public-Benefit Corporation following a business combination in February 2022.

Revenue & Expenses Breakdown

How GreenLight Biosciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:GRNA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2310-157350
31 Dec 227-167360
30 Sep 224-163340
30 Jun 223-154310
31 Mar 222-129260
31 Dec 212-112200
30 Sep 211-86170
30 Jun 212-89150
31 Mar 212-75130
31 Dec 202-53110
31 Dec 193-3790

Quality Earnings: GRNA is currently unprofitable.

Growing Profit Margin: GRNA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GRNA is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Accelerating Growth: Unable to compare GRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).


Return on Equity

High ROE: GRNA has a negative Return on Equity (-717.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/25 05:08
End of Day Share Price 2023/07/21 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GreenLight Biosciences Holdings is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurlesonCanaccord Genuity